137 related articles for article (PubMed ID: 29349823)
1. Tibolone and risk of gynecological hormone sensitive cancer.
Løkkegaard ECL; Mørch LS
Int J Cancer; 2018 Jun; 142(12):2435-2440. PubMed ID: 29349823
[TBL] [Abstract][Full Text] [Related]
2. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.
de Vries CS; Bromley SE; Thomas H; Farmer RD
Drug Saf; 2005; 28(3):241-9. PubMed ID: 15733028
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
4. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro estrogenic and progestagenic actions of Tibolone.
Sadarangani A; Salgado AM; Kato S; Pinto M; Carvajal A; Monso C; Owen GI; Vigil P
Biol Res; 2005; 38(2-3):245-58. PubMed ID: 16238103
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of the endometrium in patients treated with tibolone.
Yazigi R; Sahid S; Contreras L; Rodriguez T
Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
[TBL] [Abstract][Full Text] [Related]
7. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
[TBL] [Abstract][Full Text] [Related]
8. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study.
Mørch LS; Kjaer SK; Keiding N; Løkkegaard E; Lidegaard Ø
Int J Cancer; 2016 Mar; 138(6):1506-15. PubMed ID: 26421912
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy and different ovarian cancers: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
11. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition.
Allen NE; Tsilidis KK; Key TJ; Dossus L; Kaaks R; Lund E; Bakken K; Gavrilyuk O; Overvad K; Tjønneland A; Olsen A; Fournier A; Fabre A; Clavel-Chapelon F; Chabbert-Buffet N; Sacerdote C; Krogh V; Bendinelli B; Tumino R; Panico S; Bergmann M; Schuetze M; van Duijnhoven FJ; Bueno-de-Mesquita HB; Onland-Moret NC; van Gils CH; Amiano P; Barricarte A; Chirlaque MD; Molina-Montes ME; Redondo ML; Duell EJ; Khaw KT; Wareham N; Rinaldi S; Fedirko V; Mouw T; Michaud DS; Riboli E
Am J Epidemiol; 2010 Dec; 172(12):1394-403. PubMed ID: 20961969
[TBL] [Abstract][Full Text] [Related]
12. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
14. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
16. Tibolone: cancers of the breast and endometrium.
Prescrire Int; 2006 Jun; 15(83):107. PubMed ID: 16764100
[TBL] [Abstract][Full Text] [Related]
17. Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
Reinholdt K; Kjaer SK; Guleria S; Frederiksen K; Mellemkjær L; Munk C; Jensen A
Gynecol Oncol; 2020 May; 157(2):549-554. PubMed ID: 32139149
[TBL] [Abstract][Full Text] [Related]
18. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
19. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
Jamin C; Bourg F; Legeai J; Senoussi S
Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
[TBL] [Abstract][Full Text] [Related]
20. Endometrial effects of tibolone.
Archer DF; Hendrix S; Gallagher JC; Rymer J; Skouby S; Ferenczy A; den Hollander W; Stathopoulos V; Helmond FA
J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
